Clinical Trials on Coronary Small Vessel Disease in Hong Kong

Total 409 results

DalCor Pharmaceuticals
The Montreal Health Innovations Coordinating Center (MHICC)

Recruiting

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE-2)

Acute Coronary Syndrome

United States, Canada, Puerto Rico
Spectrum Pharmaceuticals, Inc

Terminated

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NSCLC

United States, Canada, Netherlands, Belgium, Israel, Spain, France, Italy
Boehringer Ingelheim

Completed

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Atrial Fibrillation | Percutaneous Coronary Intervention

Canada, United States, Spain, Korea, Republic of, Australia, Germany, Taiwan, Hong Kong, Thailand, United Kingdom, Turkey, Netherlands, Ireland, Hungary, Croatia, Colombia, Israel, Singapore, Italy, New Zealand, Greece, Mexico, Norway, Swed... and more
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
Pfizer

Completed

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Hepatocellular Carcinoma | Advanced Breast Cancer | Non-Small Cell Lung Cancer | Metastatic Breast Cancer | Metastatic Renal Cell Cancer | Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Gastrointestinal Stromal Tumor | Advanced Gastric Cancer | Metastatic Castration Resistant Prostate Cancer | Advanced... and other conditions

United States, Spain, Korea, Republic of, France, Australia, United Kingdom, Canada, Brazil, Argentina, Taiwan, Belgium, Colombia, Germany, Hong Kong, Mexico, Philippines, Singapore
AstraZeneca

Completed

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (PLATO)

Acute Coronary Syndrome

Sweden, United States, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Poland, Russian Federation, South Africa, Turkey, United Kingdom, Germany, Philippines, China, Hungary, Romania, Denmark, Netherlands, Norway, C... and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Lung Cancer

United States, Canada, Australia
Pfizer

Active, not recruiting

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Carcinoma, Non-Small-Cell Lung

Canada, Spain, United States, China, Korea, Republic of, United Kingdom, France, Czechia, Japan, Singapore, Taiwan, Australia, Netherlands, India, Turkey, Hong Kong, Argentina, Belgium, Germany, Italy, Mexico, Poland, Russian Federation
Pfizer

Active, not recruiting

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Taiwan, Australia, United Kingdom
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

Hong Kong, Canada, Korea, Republic of, Belgium, Australia, United States, Taiwan, United Kingdom, Germany, Italy, Japan, Austria, Thailand, Peru, Ireland, Russian Federation, Philippines, France, Brazil, Chile, Argentina, Hungary, M... and more
Boehringer Ingelheim

Approved for marketing

Afatinib Expanded Access Program

Carcinoma, Non-Small-Cell Lung

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Takeda

Active, not recruiting

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Spain, Korea, Republic of, Taiwan, Japan, China, Italy, Germany, United Kingdom, Puerto Rico
Eli Lilly and Company

Completed

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Non-Small Cell Lung Cancer

United States, Germany, Israel, Italy, Mexico, France, Poland, Romania, Spain, Taiwan, United Kingdom, Hungary, Austria, Argentina, Korea, Republic of, Greece, Turkey, India, Netherlands, Russian Federation, Canada, Norway, Sweden, Br... and more
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001)

Non-Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Any Solid Tumor

United States, Japan, Taiwan, Australia, Korea, Republic of, Israel, Spain, Switzerland, Singapore, France, Canada, Italy, Germany, United Kingdom, Hong Kong, Denmark
Pfizer

Terminated

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Australia, United States, Hungary, Germany, Italy, Korea, Republic of, Spain, Sweden, Mexico, South Africa, Taiwan, Belgium, Canada, China, Cyprus, Czech Republic, France, Greece, Hong Kong, India, Israel, Netherlands, Poland, Portugal, Switzerlan... and more
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditions

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Lung Cancer | Radiation Toxicity | Oral Complications | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States, Guam
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Lung Non-Small Cell Carcinoma | Lung Non-Small Cell Squamous Carcinoma | Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8

United States, Guam
Axio Research. LLC
National Heart, Lung, and Blood Institute (NHLBI); Abbott

Terminated

Niacin Plus Statin to Prevent Vascular Events

Myocardial Infarction | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Atherosclerosis | Cerebrovascular Accident

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Atherosclerotic Cardiovascular Disease

China, Hong Kong, Austria, Bulgaria, Norway, Peru, France, Japan, Spain, Lithuania, Philippines, Israel, Belgium, Croatia, Poland, Hungary, Chile, Mexico, Latvia, Singapore, Switzerland, Colombia, Greece, Ukraine, Turkey, Finland, United States and more
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Lung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

Carcinoma, Non-Small-Cell Lung

United States, Denmark, Taiwan, China, Canada, Spain, Japan, Germany, United Kingdom, Brazil, India, Korea, Republic of, Australia, Italy, Norway, Israel, Greece, Turkey, Netherlands, Austria, Belgium, Hong Kong, Poland, Puerto Rico, Russian... and more
Pfizer

Completed

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Carcinoma, Non-Small-Cell Lung

United States, Canada, Spain, China, Brazil, United Kingdom, Japan, Poland, Australia, France, Ireland, Taiwan, Italy, Germany, Netherlands, Korea, Republic of, Bulgaria, Greece, Hong Kong, Hungary, Russian Federation, Sweden
Pfizer

Completed

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Carcinoma, Non-Small-Cell Lung

United States, Canada, Spain, China, United Kingdom, Poland, France, Ireland, Japan, Taiwan, Germany, Netherlands, Italy, Brazil, Russian Federation, Korea, Republic of, Australia, Bulgaria, Greece, Hong Kong, Hungary, Sweden
Eli Lilly and Company
Duke Clinical Research Institute; Daiichi Sankyo Co., Ltd.

Completed

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS)

Acute Coronary Syndrome

Argentina, Brazil, Canada, Italy, China, Puerto Rico, Australia, Romania, Russian Federation, France, Germany, United States, Belgium, Bulgaria, Poland, Ukraine, United Kingdom, Colombia, Hungary, Philippines, Croatia, Denmark, India, Chil... and more
Point Therapeutics

Terminated

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Neoplasms, Pulmonary

United States
Bristol-Myers Squibb
Pfizer; Duke Clinical Research Institute

Terminated

Phase III Acute Coronary Syndrome (APPRAISE-2)

Acute Coronary Syndrome

Argentina, China, India, Japan, Korea, Republic of, Mexico, Poland, South Africa, Sweden, United States, Chile, Spain, United Kingdom, Australia, Brazil, Colombia, Austria, Denmark, Germany, Belgium, Hungary, Israel, Peru, Romania, Russian... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)

Carcinoma, Non-Small-Cell Lung

United States, France, Canada, China, Israel, Belgium, United Kingdom, Italy, Argentina, Japan, Taiwan, Thailand, Korea, Republic of, Malaysia, Poland, Australia, Spain, Netherlands, Hungary, Turkey, Germany, India, Brazil, Russian Federation and more
Sanofi

Completed

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy (TAO)

Acute Coronary Syndrome

Austria, Korea, Republic of, Brazil, Belarus, India, Latvia, Belgium, Canada, Israel, Portugal, Germany, United States, Argentina, Australia, Bulgaria, Chile, Colombia, Croatia, Czech Republic, Egypt, Estonia, France, Greece, Hong Kong, Hungar... and more
GlaxoSmithKline
The TIMI Study Group

Completed

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52)

Acute Coronary Syndrome

United States, France, Netherlands, Ukraine, Germany, Taiwan, Bulgaria, Hungary, Poland, Russian Federation, Argentina, Belgium, Peru, Philippines, Sweden, Thailand, Israel, Spain, Korea, Republic of, Australia, Czechia, Japan, New... and more
Bristol-Myers Squibb

Completed

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Lung Cancer - Non Small Cell Squamous

Belgium, Brazil, China, Germany, Hong Kong, Japan, Korea, Republic of, Taiwan, Thailand, United States, Spain, Australia, Italy, Netherlands, United Kingdom, Denmark, France, Argentina, Austria, Canada, Chile, Colombia, Czechia, Hungary, Irela... and more
Janssen Research & Development, LLC

Recruiting

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2)

Carcinoma, Non-Small-Cell Lung

Taiwan, United States, Korea, Republic of, Germany, France, China, Japan, Italy, Spain, Puerto Rico
Sanifit Therapeutics S. A.
Clinipace Worldwide

Completed

Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

Cardiovascular Diseases | Cardiovascular Abnormalities | ESRD | Coronary Artery Calcification | Endstage Renal Disease | Calcifications, Vascular

Spain, United States, United Kingdom
Pfizer

Completed

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)

Non Squamous Lung Cancer

United States, Switzerland, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Japan, Germany, Luxembourg, Australia, France, Brazil, Italy, Hong Kong, China, Belgium, Russian Federation, Austria, Finland, Portugal and more
AstraZeneca

Completed

Iressa Expanded Access Program (EAP)

Carcinoma | Neoplasm | Non-small-cell Lung | Metastases

United States
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland
Sanofi

Completed

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA)

Acute Coronary Syndrome

Belgium, China, Japan, Denmark, United States, Belarus, Mexico, Philippines, Israel, Austria, Serbia, Estonia, Lithuania, Chile, Colombia, Germany, Latvia, Peru, Ukraine, Egypt, Italy, France, Brazil, India, Guatemala, South Africa, Taiwan, C... and more
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

Carcinoma, Non-Small-Cell Lung

United States, Australia, Brazil, Chile, China, Costa Rica, Dominican Republic, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Spain, Turkey, Portugal, Romania, South Africa, Philippines, Ukr...
Medtronic

Recruiting

Product Surveillance Registry (PSR)

Coronary Artery Disease | Renal Insufficiency | Neurological Disorders | Intracranial Aneurysm | Surgical Procedures, Operative | Respiratory Therapy | Minimally Invasive Surgical Procedures | Cardiac Rhythm Disorders | Urological Disorders | Cardiovascular Disorders | Digestive Disorders | Mechanical Circulatory... and other conditions

China, France, Italy, United States, Spain, Australia, Belgium, Denmark, Germany, Greece, Hungary, Israel, Japan, Korea, Republic of, Malaysia, Netherlands, Norway, Portugal, Serbia, Sweden, Switzerland, United Kingdom, Argentina, Brazil and more
AstraZeneca

Recruiting

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)

Carcinoma, Non-Small-Cell Lung

United States, China, Israel, United Kingdom, Korea, Republic of, Canada, Italy, Poland, Spain, Belgium, Netherlands, Japan, Germany, Brazil, France, Turkey, Russian Federation, Greece, Australia, Puerto Rico
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER)

Non Small Cell Lung Cancer

Italy, United States, Spain, Germany, Korea, Republic of, Poland, Romania, Taiwan, Ukraine, France, Japan, Russian Federation, Austria, Israel, Greece, Brazil, Argentina, Turkey, Canada, Puerto Rico, China
Novartis Pharmaceuticals

Completed

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Carcinoma, Non-Small-Cell Lung

Italy, Spain, Germany, Japan, Taiwan, Belgium, Netherlands, Singapore, Argentina, France, Israel, Sweden, Korea, Republic of, Lebanon, United Kingdom, United States, Austria, Mexico, Norway, Russian Federation
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Germany, Japan, China, Israel, Belgium, Italy, France, Taiwan, Thailand, Korea, Republic of, Malaysia, Spain, Hungary, Turkey, Portugal, India, Brazil, Poland, Australia, Russian Federation, Mexico, Puerto Rico, U... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

Poland, Romania, Ukraine, Chile, Canada, United States, Argentina, China, Czechia, Estonia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Norway, Peru, Russian Federation, Spain, Thailand, Turkey, United...
Pfizer

Terminated

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Adenosquamous | Carcinoma, Large Cell

United States, Bulgaria, Canada, Ukraine, Greece, Austria, France, Korea, Republic of, Poland, Russian Federation, Spain, Turkey, Finland, Hungary, Taiwan, Italy, Japan, Australia, Germany, Brazil, India, Puerto Rico, Czech Republic, ... and more
National Cancer Institute (NCI)

Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Canada
AstraZeneca

Recruiting

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

NSCLC

China, United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, Vietnam, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, Turkey, India, Peru, Poland, Sweden, Bulgaria, Greece, Mexico, Denmark
Takeda

Completed

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE)

Diabetes Mellitus, Type 2 | Acute Coronary Syndrome

United States, France, Italy, Poland, Ukraine, United Kingdom, Belgium, Germany, Hong Kong, Argentina, Chile, Colombia, Israel, Mexico, Portugal, Bulgaria, Malaysia, Romania, Serbia, South Africa, Japan, Canada, Finland, Taiwan, Korea,... and more

Clinical Trials on Coronary Small Vessel Disease in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations